Hisun’s Biosimilar Enbrel To Get CFDA Site Inspection
This article was originally published in PharmAsia News
The China FDA’s website indicates that Hisun Pharma’s “AnBaiNuo”, a biosimilar version of Amgen and Pfizer’s Enbrel (etanercept), will be on-site inspected within this month for drug registration purposes.
You may also be interested in...
Abbott reported third-quarter 2020 global sales of $8.9bn, driven by its strong position in COVID-19 tests. See what Abbott’s CEO Robert Ford said about it here.
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.